Korean J Physiol Pharmacol.  2012 Apr;16(2):97-106. 10.4196/kjpp.2012.16.2.97.

Standard Error of Empirical Bayes Estimate in NONMEM(R) VI

• Kang D
• Bae KS
• Houk BE
• Savic RM
• Karlsson M

• KMID: 2071754
• DOI: http://doi.org/10.4196/kjpp.2012.16.2.97

Abstract

The pharmacokinetics/pharmacodynamics analysis software NONMEM(R) output provides model parameter estimates and associated standard errors. However, the standard error of empirical Bayes estimates of inter-subject variability is not available. A simple and direct method for estimating standard error of the empirical Bayes estimates of inter-subject variability using the NONMEM(R) VI internal matrix POSTV is developed and applied to several pharmacokinetic models using intensively or sparsely sampled data for demonstration and to evaluate performance. The computed standard error is in general similar to the results from other post-processing methods and the degree of difference, if any, depends on the employed estimation options.

Keyword

NONMEM; Standard error of empirical bayes estimate; Nonlinear mixed effects modeling

MeSH Terms

Bays

Figure

• 

  Fig. 1 NONMEM® VI control stream to obtain standard error of empirical Bayes estimates using POSTV.

Reference

1. Lacroix BD, Friberg LE, Karlsson MO. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. J Pharmacokinet Pharmacodyn. 2012; 39:177–193. PMID: 22270323.

2. PsN: perl-speaks-NONMEM; ©2008 by Mats Karlsson, Niclas Jonsson and Andrew Hooker. psn.sourceforge.net [Internet]. cited 2012 Feb 15. Available from: http://psn.sourceforge.net.

3. Beal SL, Sheiner LB, Boeckmann AJ, editors. NONMEM Users Guides - Part VII. 1989-2006. Ellicott City, Maryland, USA: Icon Development Solutions.

4. Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007; 34:575–593. PMID: 17620001.

5. Pawitan Y. In all likelihood: statistical modelling and inference using likelihood. 2001. New York: Oxford University Press.

6. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User' s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. 2009. Los Angeles: Biomedical Simulations Resource.

7. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009; 11:558–569. PMID: 19649712.

8. Balram C, Lim BL, Lee EJ, Wong SY, Ang B. Validity of Bayesian forecasting programme in therapeutic drug monitoring of vancomycin in a surgical intensive care unit: a prospective evaluation. Ann Acad Med Singapore. 1996; 25:492–495. PMID: 8893916.

9. el Desoky E, Meinshausen J, Bühl K, Engel G, Harings-Kaim A, Drewelow B, Klotz U. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit. 1993; 15:281–288. PMID: 8236362.

10. Pons G, Tréluyer JM, Dimet J, Merlé Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit. 2002; 24:9–14. PMID: 11805715.

11. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007; 82:17–20. PMID: 17571070.

12. Park K, Verotta D, Gupta SK, Sheiner LB. Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile. J Pharmacokinet Biopharm. 1998; 26:471–492. PMID: 10214563.

13. Ette EI, Williams PJ. Pharmacometrics - The Science of Quantitative Pharmacology. 2007. Hoboken, New Jersey: John Wiley & Sons, Inc..